With First Dibs on vaccines, rich countries have ‘cleared the shelves’



[ad_1]

And while Pfizer vaccines are already reaching Britain, Canada and the United States, it is unclear when they will reach other countries. Mexico, according to an announcement, could receive its first vaccines at any time in the next 12 months.

Clemens Auer, a chief negotiator for the European Union, said in an email that his contract with Pfizer for 200 million doses came with a “fixed delivery schedule” but that he was withholding the details from the public. “The details don’t matter much,” he said, given the large volume of promising vaccines the EU had sourced.

In Canada, the government has faced questions about its contract with Moderna. The country reached an agreement in August for 20 million doses, with an option for an additional 36 million. The United States announced a deal for up to 500 million doses soon after, and Britain and the European Union announced their own deals last month.

So when Moderna recently said its first 20 million would go to the United States, Canadian politicians were accused of letting their country lose its place. It was not widely known that, as a condition of receiving financial support from the United States, Moderna had promised Americans their first doses.

Erin O’Toole, the conservative leader of the Canadian Parliament, introduced a motion that requires the government to publish the dates of fulfillment of their requests, saying that citizens “deserve to know when they can expect each type of vaccine.”

Even if other promising candidates, like Johnson & Johnson, get approval early and take the pressure off Pfizer and Moderna, there is no guarantee that the companies will be able to meet their commitments next year.

“People think that just because we’ve shown in phase 3 clinical trials that we have safe and effective vaccines, the taps are about to open all the way,” said Dr. Richard Hatchett, director of the Coalition for Preparedness. Epidemics, one of the global non-profit organizations leading the Covax program with WHO “The challenges of scaling up manufacturing are significant and difficult.

[ad_2]